📑 Table of Contents▼
For other uses, see Methylethyltryptamine (disambiguation).

Methylethyltryptamine
Clinical data
Other namesMET; N-Methyl-N-ethyltryptamine; N,N-MET
Routes of
administration		Oral; Vaporized/inhaled[1][2][3]
Drug classSerotonergic psychedelic; Hallucinogen; Serotonin 5-HT2A and 5-HT2C receptor agonist; Serotonin releasing agent
ATC code
  • None
Pharmacokinetic data
Onset of actionUnknown[1]
Duration of actionUnknown[1]
Identifiers
  • N-ethyl-2-(1H-indol-3-yl)-N-methylethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H18N2
Molar mass202.301ย gยทmolโˆ’1
3D model (JSmol)
  • c1cccc2c1c(c[nH]2)CCN(CC)C
  • InChI=1S/C13H18N2/c1-3-15(2)9-8-11-10-14-13-7-5-4-6-12(11)13/h4-7,10,14H,3,8-9H2,1-2H3ย checkY
  • Key:MYEGVMLMDWYPOA-UHFFFAOYSA-Nย checkY
ย ย (verify)

Methylethyltryptamine (MET), also known as N-methyl-N-ethyltryptamine (N,N-MET), is a psychedelic drug of the tryptamine family.[1][4] It is taken orally or via inhalation.[1][3]

The drug acts as an agonist of the serotonin 5-HT2 receptors and to a lesser extent as a serotonin releasing agent.[5] It is closely related to dimethyltryptamine (DMT) and to diethyltryptamine (DET).[6][7]

MET appears to have been first described in the literature in 1981.[8] It was only briefly mentioned in Alexander Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved).[1] The drug was encountered as a novel designer drug in Europe in 2014.[9]

Use and effects

edit

MET was briefly mentioned in Alexander Shulgin's TiHKAL (Tryptamines I Have Known and Loved) and other publications, where he has stated it to be orally active as a psychedelic at doses of 80 to 100ย mg.[1][4][2] Its duration, onset, and peak were not provided.[1] The free base of MET has been reported to be active as a psychedelic via vaporization at a dose of 15ย mg per informal anecdotal reports.[2][3] Very little information is available on the effects of MET.[2] However, its effects have been reported to include hallucinations, euphoria, tactile enhancement, cognitive effects, pupil dilation, muscle cramps, teeth grinding, and increased heart rate and blood pressure.[2]

Interactions

edit
See also: Psychedelic drug ยงย Interactions, and Trip killer ยงย Serotonergic psychedelic antidotes

Pharmacology

edit

Pharmacodynamics

edit

MET is a serotonin 5-HT2A and 5-HT2C receptor partial agonist.[5] It shows very weak activity as an agonist of the serotonin 5-HT1A and 5-HT2B receptors.[5] In addition to acting at the serotonin 5-HT2 receptors, MET is a serotonin releasing agent with lower potency.[5] It produces the head-twitch response, a behavioral proxy of psychedelic effects, in animals.[7][5]

Chemistry

edit

MET, also known as N-methyl-N-ethyltryptamine, is a substituted tryptamine derivative.[1][4][5] It is closely related to N,N-dimethyltryptamine (DMT) and to other N,N-dialkylated tryptamines.[1][4][5]

Analogues

edit

Analogues of MET besides DMT include DET, DPT, DiPT, DBT, MiPT, MBT, EPT, EiPT, and PiPT, among others.[1][4] Derivatives of MET include 4-HO-MET, 5-HO-MET, 5-MeO-MET, bretisilocin (5-fluoro-MET; GM-2505), and 7-F-5-MeO-MET, among others.[1][4]

History

edit

MET appears to have first been described in the literature by 1981.[8] It was specifically mentioned in Michael Valentine Smith's Psychedelic Chemistry.[8] Subsequently, MET was briefly described in Alexander Shulgin's TiHKAL (Tryptamines I Have Known and Loved) in 1997.[1] MET was encountered as a novel designer drug in Europe in 2014.[9]

Society and culture

edit
edit

Canada

edit

MET is not a controlled substance in Canada as of 2025.[10]

United States

edit

MET is not an explicitly controlled substance in the United States.[11] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

See also

edit

References

edit
  1. ^ a b c d e f g h i j k l m Shulgin AT, Shulgin A (1997). TiHKAL: The Continuation (1stย ed.). Berkeley, CA: Transform Press. ISBNย 978-0-9630096-9-2. OCLCย 38503252. Retrieved 30 January 2025. MET; positive, psychedelic; 80โ€“100 mg [...] Lying midway between DMT and DIPT is the ethyl compound, N-ethyl-N-methyltryptamine, or MET. It can be made by adding ethyl acetate to a reaction mixture where the formamide of tryptamine (see under NMT) has been reduced to NMT but there is still a goodly excess of hydride still remaining. The free base, as an oil, shows oral activity in the eighty to one hundred milligram range, so going from a methyl to an ethyl does indeed protect the compound from total enzymatic annihilation when taken orally.
  2. ^ a b c d e Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardรฒ FP, Huestis MA (December 2020). "Toxicology and Analysis of Psychoactive Tryptamines". Int J Mol Sci. 21 (23): 9279. doi:10.3390/ijms21239279. PMCย 7730282. PMIDย 33291798. N-methyl-N-ethyltryptamine (MET): MET is structurally related to DMT but little scientific information is available on its pharmacology or toxicity in humans. Inhalation of 15 mg freebase MET or 80โ€“100 mg oral freebase MET produce effects [73]. Anecdotal reports describe the most common physical and psychological effects as physical euphoria, tactile enhancement, increased heart rate and blood pressure, muscle cramps, teeth grinding, pupil dilation, hallucinations and cognitive effects [73].
  3. ^ a b c "That's okay, you're good" MET trip report - The Vaults of Erowid
  4. ^ a b c d e f Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp.ย 67โ€“137. ISBNย 978-0-12-433951-4. Retrieved 1 February 2025. Table 3.19 N,N-Dialkyl homologues of DMT: [...] R1: Me-. R2: Et-. common name: methyl-ethyltryptamine. code: MET. potency: mg: 80โ€“100. x-DMT: 1.
  5. ^ a b c d e f g US 11440879, Kruegel AC, "Methods of treating mood disorders", issued 13 September 2022, assigned to Gilgamesh Pharmaceuticals Inc.ย 
  6. ^ Schifano F, Orsolini L, Papanti D, Corkery J (2016). "NPS: Medical Consequences Associated with Their Intake". Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences. Vol.ย 32. pp.ย 351โ€“380. doi:10.1007/7854_2016_15. ISBNย 978-3-319-52442-9. PMIDย 27272067.
  7. ^ a b Halberstadt AL, Geyer MA (2018). "Effect of Hallucinogens on Unconditioned Behavior". Behavioral Neurobiology of Psychedelic Drugs. Curr Top Behav Neurosci. Vol.ย 36. pp.ย 159โ€“199. doi:10.1007/7854_2016_466. ISBNย 978-3-662-55878-2. PMCย 5787039. PMIDย 28224459. The HTR has also been observed in rodents treated with N-methyl-N-ethyltryptamine (MET), N,N-diethyltryptamine (DET), N,N-dipropyltryptamine (DPT), N,N-diisopropyltryptamine (DIPT), and N,N-diallyltryptamine (DALT) (Fantegrossi et al. 2008; Smith et al. 2014; Carbonaro et al. 2015; Halberstadt and Klein, unpublished observations).
  8. ^ a b c Smith MV (1981). Psychedelic Chemistry. Loompanics Unlimited. ISBNย 978-0-915179-10-7. Retrieved 20 February 2025.
  9. ^ a b European Monitoring Centre for Drugs and Drug Addiction., European Police Office. (2015). EMCDDAโ€“Europol 2014 annual report on the implementation of Council Decision 2005/387/JHA: in accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances: implementation reports. Publications Office. doi:10.2810/112317. ISBNย 978-92-9168-821-0. Retrieved 20 February 2025.
  10. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
  11. ^ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
edit

๐Ÿ“š Artikel Terkait di Wikipedia

Methylethyltryptamine (disambiguation)

Methylethyltryptamine (abbreviated as MET) may refer to: N-Methyl-N-ethyltryptamine (MET or N,N-MET) 4-Methyl-ฮฑ-ethyltryptamine (4-Me-ฮฑET or 7-Me-AET)

4-HO-MET

analogue of psilocin (4-HO-DMT) and is the 4-hydroxyl analogue of methylethyltryptamine (MET). 4-HO-MET was discovered by Alexander Shulgin in the 1970s

5-HO-MET

been extended to an ethyl group. The drug is also an analogue of methylethyltryptamine (MET), 4-HO-MET (metocin), and 5-MeO-MET. 5-HO-MET was reported

Bretisilocin

dimethyltryptamine (DMT) and is the 5-fluorinated derivative of methylethyltryptamine (MET). Bretisilocin's route of administration is intravenous infusion

Dimethyltryptamine

(mebufotenin; N,N,O-trimethylserotonin). Some further examples include methylethyltryptamine (MET), diethyltryptamine (DET), methylpropyltryptamine (MPT), dipropyltryptamine

5-MeO-MET

drug of the tryptamine family related to psychedelic drugs like methylethyltryptamine (MET) and 5-MeO-DMT. 5-MeO-MET was not included nor mentioned in

Methylpropyltryptamine

psychedelic drug of the tryptamine family. It is a homologue of methylethyltryptamine (MET). In his book TiHKAL (Tryptamines I Have Known and Loved),

Dimethyltryptamine (disambiguation)

tryptamine Methyltryptamine Ethyltryptamine Trimethyltryptamine Methylethyltryptamine Dimethylserotonin This set index article lists chemical compounds